相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan
Pang-Hsiang Liu et al.
BMC HEALTH SERVICES RESEARCH (2010)
Cost-effectiveness of human papillomavirus vaccination and screening in Spain
Mireia Diaz et al.
EUROPEAN JOURNAL OF CANCER (2010)
A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme
Anne Dee et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2010)
Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark
Jens Olsen et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2010)
Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis
Jane J. Kim
LANCET INFECTIOUS DISEASES (2010)
Impact of vaccinating boys and men against HPV in the United States
Elamin H. Elbasha et al.
VACCINE (2010)
The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary
Erik J. Dasbach et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise
Saku Torvinen et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Jane J. Kim et al.
ANNALS OF INTERNAL MEDICINE (2009)
Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico
Luz Myriam Reynales-Shigematsu et al.
ARCHIVES OF MEDICAL RESEARCH (2009)
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
Andrea M. Anonychuk et al.
BMC PUBLIC HEALTH (2009)
Health and economic impact associated with a quadrivalent HPV vaccine in Italy
F. S. Mennini et al.
GYNECOLOGIC ONCOLOGY (2009)
HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness
Veerle M. H. Coupe et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening
Nancy Thiry et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands
Inge M. C. M. de Kok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine A Systematic Review
Fawziah Marra et al.
PHARMACOECONOMICS (2009)
Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
Lieven Annemans et al.
PHARMACOECONOMICS (2009)
Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries
Lisandro Colantonio et al.
VACCINE (2009)
The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa
Edina Sinanovic et al.
VACCINE (2009)
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands
R. M. Rogoza et al.
VACCINE (2009)
Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria
Ingrid Zechmeister et al.
VACCINE (2009)
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
Jane J. Kim et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
The economic burden of noncervical human papillomavirus disease in the United States
Delphine Hu et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
E. J. Dasbach et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2008)
Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
M. Diaz et al.
BRITISH JOURNAL OF CANCER (2008)
A Multi-Type HPV Transmission Model
Elamin H. Elbasha et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2008)
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination
Jeremy D. Goldhaber-Fiebert et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Health and economic implications of HPV vaccination in the United States
Jane J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination
Donna Debicki et al.
VACCINE (2008)
Exploring the cost-effectiveness of HPV vaccination in Vietnam: Insights for evidence-based cervical cancer prevention policy
Jane J. Kim et al.
VACCINE (2008)
Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model
Cara Usher et al.
VACCINE (2008)
Cost-effectiveness of vaccination against cervical cancer:: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios
Eugenio Suarez et al.
VACCINE (2008)
Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis
Raina M. Rogoza et al.
VACCINE (2008)
Economic evaluation of human papillomavirus vaccination in the United Kingdom
Mark Jit et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation
Ralph P. Insinga et al.
VACCINE (2007)
Human papillomavirus vaccination in males
Anna R. Giuliano
GYNECOLOGIC ONCOLOGY (2007)
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting
J. J. Kim et al.
BRITISH JOURNAL OF CANCER (2007)
Cost-utility analysis of vaccination against HPV in Israel
Gary Michael Ginsberg et al.
VACCINE (2007)
A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
Shalini Kulasingam et al.
SEXUAL HEALTH (2007)
Cost-effectiveness of HPV 16, 18 vaccination in Brazil
Sue J. Goldie et al.
VACCINE (2007)
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update
Jennifer S. Smith et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
Marc Brisson et al.
VACCINE (2007)
Multiparameter calibration of a natural history model of cervical cancer
Jane J. Kim et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK
M. Kohli et al.
BRITISH JOURNAL OF CANCER (2007)
Model for assessing human papillomavirus vaccination strategies
Elamin H. Elbasha et al.
EMERGING INFECTIOUS DISEASES (2007)
Review of the economic and quality-of-life burden of cervical human papillomavirus disease
Rachael L. Fleurence et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa et al.
BRITISH JOURNAL OF CANCER (2006)
Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
Charles J. N. Lacey et al.
VACCINE (2006)
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
Luisa L. Villa et al.
VACCINE (2006)
The global health burden of infection -associated cancers in the year 2002
Donald Maxwell Parkin
INTERNATIONAL JOURNAL OF CANCER (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia - A Randomized controlled trial
C Mao et al.
OBSTETRICS AND GYNECOLOGY (2006)
Human papillomavirus: The burden of infection
Dorothy Wiley et al.
OBSTETRICAL & GYNECOLOGICAL SURVEY (2006)
Vulvar intraepithelial neoplasia - Aspects of the natural history and outcome in 405 women
RW Jones et al.
OBSTETRICS AND GYNECOLOGY (2005)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
Role of herd immunity in determining the effect of vaccines against sexually transmitted disease
GP Garnett
JOURNAL OF INFECTIOUS DISEASES (2005)
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US - Analytic framework and review of the literature
RP Insinga et al.
PHARMACOECONOMICS (2005)
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
SJ Goldie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Evaluating human papillomavirus vaccination programs
AV Taira et al.
EMERGING INFECTIOUS DISEASES (2004)
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs
SL Kulasingam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
A controlled trial of a human papillomavirus type 16 vaccine
LA Koutsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Benefits and costs of using HPV testing to screen for cervical cancer
JS Mandelblatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
分享论文
